Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
24.04
+0.31 (1.31%)
Aug 7, 2025, 12:58 PM - Market open
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,062,886
Profits / Employee
-$321,372
Market Cap
3.04B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 710 | 4 | 0.57% |
Dec 31, 2023 | 706 | -61 | -7.95% |
Dec 31, 2022 | 767 | 291 | 61.13% |
Dec 31, 2021 | 476 | 102 | 27.27% |
Dec 31, 2020 | 374 | 139 | 59.15% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APLS News
- 5 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Apellis Pharmaceuticals: The Picture Becomes Clearer - Seeking Alpha
- 7 days ago - Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 9 days ago - FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio - Benzinga
- 9 days ago - FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - GlobeNewsWire
- 14 days ago - Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - GlobeNewsWire
- 23 days ago - Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - GlobeNewsWire
- 5 weeks ago - Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) - PRNewsWire